A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Clinical trial NCT03452137 · TERMINATED
Trial details
- NCT number
- NCT03452137
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-03
- Primary completion
- 2023-09-27
- Enrollment
- 406
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.